Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 11Active not recruiting 7Recruiting 6Terminated 4Unknown 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6Thoracic 1Other solid neoplasm 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 51Carcinoma, Non-Small-Cell Lung 40Carcinoma, Renal Cell 27Carcinoma, Hepatocellular 18Neoplasms 15Neoplasm Metastasis 15Lung Neoplasms 14Colorectal Neoplasms 14Stomach Neoplasms 13Adenocarcinoma Of Esophagus 11Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Transitional Cell 8Brain Neoplasms 8Hodgkin Disease 7Skin Neoplasms 6Sarcoma 6Kidney Neoplasms 6Esophageal Neoplasms 6Triple Negative Breast Neoplasms 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Clear-cell metastatic renal cell carcinoma 5Carcinoma, Merkel Cell 5Uveal Melanoma 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Recurrence 4Neuroendocrine Tumors 4Nasopharyngeal Carcinoma 4Mesothelioma 4

Interventions

cabozantinib 7pembrolizumab 6Nivolumab 6Ipilimumab 5Axitinib 5Radiosurgery 3Blood Specimen Collection 3zimberelimab 2lenvatinib 2Ultrasonography 2Radiotherapy 2Biopsy 2tislelizumab 1polyethylene glycol 3350 1pazopanib 1palbociclib 1orellanine 1olaparib 1gallium Ga 68 dotatate 1fludarabine 1cyclopropapyrroloindole 1brodalumab 1belzutifan 1atezolizumab 1anlotinib 1adagrasib 1Watchful Waiting 1Vincristine 1Therapeutics 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Kidney Neoplasms × Nivolumab × Clear all
NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

Phase 1/2 Recruiting
126 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT07401875 2026-04-02

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

M.D. Anderson Cancer Center

Phase 1 Recruiting
35 enrolled
Genitourinary

Kidney Neoplasms

NCT07028125 2025-10-07

CANIQOL

Centre Francois Baclesse

Phase 4 Recruiting
83 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT06934057 2025-09-24

CABOLD

Gustave Roussy, Cancer Campus, Grand Paris

Phase 4 Recruiting
50 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04322955 2025-04-25

Cyto-KIK

Columbia University

Phase 2 Recruiting
48 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06364631 2025-01-16

CARE1

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Recruiting
1,250 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡